Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience
- 1 November 1982
- Vol. 50 (9) , 1669-1675
- https://doi.org/10.1002/1097-0142(19821101)50:9<1669::aid-cncr2820500902>3.0.co;2-n
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Oral melphalan kineticsClinical Pharmacology & Therapeutics, 1979
- Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1- nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myelomaBlood, 1979
- Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGBBlood, 1979
- Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962), cyclophosphamide plus prednisone (ABC-P) in melphalan-resistant multiple myelomaCancer, 1978
- Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocolThe American Journal of Medicine, 1977
- Combination therapy for multiple myelomaCancer, 1977
- DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSEThe Lancet, 1976
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorshipBiometrika, 1970
- Latin Squares to Balance Immediate Residual, and Other Order, EffectsBiometrics, 1961